- About
- Specialties & Areas of Expertise
- Locations & Patient Information
- Education & Research
- Accepted Insurance
- External Professional Relationships
Daniel Olson, MD, is a highly skilled and compassionate oncologist who has dedicated his career to diagnosing and treating skin cancers and sarcomas. As an expert in skin cancers and sarcomas, Dr. Olson has extensive knowledge and expertise in identifying common types of skin cancers affecting patients – primarily melanomas – as well as uncommon skin cancers and soft tissue and bone sarcomas. He delivers the latest advancements in diagnosis and treatment methods, including immuno, targeted and traditional chemotherapies in addition to offering new cell-based immunotherapies such as tumor-infiltrating lymphocyte (TIL) therapy. He also performs diagnostic procedures to ensure accurate skin cancer and sarcoma diagnosis and staging.
Because he understands that each patient is unique and has individual needs, Dr. Olson’s practice is centered around providing personalized care to his patients. He takes the time to listen to his patients' concerns, answer their questions and develop a treatment plan that is tailored to their specific circumstances. His goal is to not only treat skin cancers and sarcomas but to also improve his patients' overall quality of life. Dr. Olson previously served in the United States Peace Corps in Guatemala and readily takes care of Spanish-speaking patients.
Additionally, Dr. Olson’s research focuses on developing new immunotherapy treatments for solid tumors. He runs multiple immunotherapy clinical trials in the Developmental Therapeutics Program and also helps manage solid tumor cell therapy trials within the Cell Therapy Program. Dr. Olson sees and treats patients with any solid tumors that have grown despite standard treatment regimens as part of these immunotherapy clinical trials.
Because he understands that each patient is unique and has individual needs, Dr. Olson’s practice is centered around providing personalized care to his patients. He takes the time to listen to his patients' concerns, answer their questions and develop a treatment plan that is tailored to their specific circumstances. His goal is to not only treat skin cancers and sarcomas but to also improve his patients' overall quality of life. Dr. Olson previously served in the United States Peace Corps in Guatemala and readily takes care of Spanish-speaking patients.
Additionally, Dr. Olson’s research focuses on developing new immunotherapy treatments for solid tumors. He runs multiple immunotherapy clinical trials in the Developmental Therapeutics Program and also helps manage solid tumor cell therapy trials within the Cell Therapy Program. Dr. Olson sees and treats patients with any solid tumors that have grown despite standard treatment regimens as part of these immunotherapy clinical trials.
Specialties
Areas of Expertise
Board Certifications
- Medical Oncology
- Internal Medicine
Languages Spoken
- English
- Spanish
Medical Education
- Rush University Medical College
Residency
- Northwestern University Feinberg School of Medicine
Fellowship
- University of Chicago Medicine
News & Research
Insurance
- Aetna Better Health *see insurance page
- Aetna HMO (specialists only)
- Aetna Medicare Advantage HMO & PPO
- Aetna POS
- Aetna PPO
- BCBS Blue Precision HMO (specialists only)
- BCBS HMO (HMOI) (specialists only)
- BCBS Medicare Advantage HMO & PPO
- BCBS PPO
- Cigna HMO
- Cigna POS
- Cigna PPO
- CountyCare *see insurance page
- Humana Medicare Advantage Choice PPO
- Humana Medicare Advantage Gold Choice PFFS
- Humana Medicare Advantage Gold Plus HMO
- Medicare
- Multiplan PPO
- PHCS PPO
- United Choice Plus POS/PPO
- United Choice HMO (specialists only)
- United Options (PPO)
- United Select (HMO & EPO) (specialists only)
- United W500 Emergent Wrap
- University of Chicago Health Plan (UCHP)
Our list of accepted insurance providers is subject to change at any time. You should contact your insurance company to confirm UChicago Medicine participates in their network before scheduling your appointment. If you have questions regarding your insurance benefits at UChicago Medicine, please contact our financial counseling team at OPSFinancialCounseling@uchospitals.edu.
UChicago Medicine is committed to fostering a corporate culture of ethical behavior and integrity in all matters related to compliance with the laws and regulations that govern the delivery of healthcare. This aspiration is central to supporting patient care, research, and teaching at UChicago Medicine.
Some of our physicians and health professionals collaborate with external pharmaceutical, medical device, or other medical related entities to develop new treatments and products to improve clinical outcomes for patients. In some instances, the physician has ownership interests in the external entity and/or is compensated for advising or speaking about the entity’s products or treatments. These payments may include compensation for consulting and speaking engagements, equity, and/or royalties for products invented by our physicians. To assure objectivity and integrity in patient care, UChicago Medicine requires all physicians and health professionals to report their relationships and financial interests with external entities on an annual basis. This information is used to review relationships and transactions that might give rise to potential financial conflicts of interest, and when considered to be significant a management plan to mitigate any biases is created.
If you are a patient at UChicago Medicine and would like more information about your physician’s external relationships, please talk with your physician. You may also visit the Centers for Medicare & Medicaid Services (CMS) Open Payments website at https://openpaymentsdata.cms.gov/ . CMS Open Payments is a national disclosure program that promotes a more transparent and accountable health care system. It houses a publicly accessible database of payments that reporting entities, including drug and medical device companies, make to covered recipients like physicians and hospitals.
Information in the CMS Open Payments database could potentially contain inaccurately reported and out of date payment information. All information is open to personal interpretation, if there are questions about the data, patients and their advocates should speak directly to their health care provider for a better understanding.
Some of our physicians and health professionals collaborate with external pharmaceutical, medical device, or other medical related entities to develop new treatments and products to improve clinical outcomes for patients. In some instances, the physician has ownership interests in the external entity and/or is compensated for advising or speaking about the entity’s products or treatments. These payments may include compensation for consulting and speaking engagements, equity, and/or royalties for products invented by our physicians. To assure objectivity and integrity in patient care, UChicago Medicine requires all physicians and health professionals to report their relationships and financial interests with external entities on an annual basis. This information is used to review relationships and transactions that might give rise to potential financial conflicts of interest, and when considered to be significant a management plan to mitigate any biases is created.
If you are a patient at UChicago Medicine and would like more information about your physician’s external relationships, please talk with your physician. You may also visit the Centers for Medicare & Medicaid Services (CMS) Open Payments website at https://openpaymentsdata.cms.gov/ . CMS Open Payments is a national disclosure program that promotes a more transparent and accountable health care system. It houses a publicly accessible database of payments that reporting entities, including drug and medical device companies, make to covered recipients like physicians and hospitals.
Information in the CMS Open Payments database could potentially contain inaccurately reported and out of date payment information. All information is open to personal interpretation, if there are questions about the data, patients and their advocates should speak directly to their health care provider for a better understanding.